- 68Ga-PSMA: a One-stop Shop in Radioactive Iodine Refractory Thyroid Cancer?
-
Lengana T, Lawal IO, Mokoala K, Vorster M, Sathekge M
- KMID: 2469589
- Nucl Med Mol Imaging.
- 2019 Dec;53(6):442-445.
- doi: 10.1007/s13139-019-00621-x
We report a case of a 47-year-old female known with metastatic papillary thyroid cancer. Her treatment history included total thyroidectomy and 3 previous radio ablations with a cumulative dose of... -
- CITED
-
- Close
- SHARE
-
- Close
- â¶â¸Gallium-Arginine-Glycine-Aspartic Acid and ¹â¸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull
-
Orunmuyi A, Modiselle , Lengana T, Ebenhan T, Vorster M, Sathekge M
- KMID: 2396588
- Nucl Med Mol Imaging.
- 2017 Sep;51(3):271-273.
- doi: 10.1007/s13139-016-0400-6
We report the case of a 32 year-old male with Chondroblastic Osteosarcoma of the skull, which was imaged with both ¹â¸[F]fluorodeoxyglucose (¹â¸F-FDG) positron emission tomography/computed tomography (PET/CT) and â¶â¸Gallium-arginine-glycine-aspartic acid... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases
-
Ankrah AO, Glaudemans AWJM, Klein HC, Dierckx RA, Sathekge M
- KMID: 2446893
- Nucl Med Mol Imaging.
- 2017 Jun;51(2):127-139.
- doi: 10.1007/s13139-016-0422-0
Human immune deficiency virus (HIV) is a leading cause of death. It attacks the immune system, thereby rendering the infected host susceptible to many HIV-associated infections, malignancies and neurocognitive disorders.... -
- CITED
-
- Close
- SHARE
-
- Close
- The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
-
Maharaj M, Heslop L, Govender T, Korowlay N, Singh A, Choudhary P, Sathekge M
- KMID: 2516692
- Nucl Med Mol Imaging.
- 2021 Jun;55(3):136-140.
- doi: 10.1007/s13139-021-00696-5
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 ( 177Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably... -
- CITED
-
- Close
- SHARE
-
- Close
